J
Jennifer Eng-Wong
Researcher at Genentech
Publications - 48
Citations - 1979
Jennifer Eng-Wong is an academic researcher from Genentech. The author has contributed to research in topics: Breast cancer & Pertuzumab. The author has an hindex of 21, co-authored 46 publications receiving 1505 citations. Previous affiliations of Jennifer Eng-Wong include National Institutes of Health & Georgetown University.
Papers
More filters
Journal ArticleDOI
Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
Minetta C. Liu,Peter G. Shields,Robert D. Warren,Philip Cohen,Mary Wilkinson,Yvonne L. Ottaviano,Suman B. Rao,Jennifer Eng-Wong,Françoise Seillier-Moiseiwitsch,Anne-Michelle Noone,Claudine Isaacs +10 more
TL;DR: The first evidence of a strong correlation between CTC results and radiographic disease progression in patients receiving chemotherapy or endocrine therapy for MBC is provided and support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC.
Journal ArticleDOI
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero,Paulo M. Hoff,Lin Shen,Atsushi Ohtsu,Manish A. Shah,Karen Cheng,Chunyan Song,Haiyan Wu,Jennifer Eng-Wong,Katherine Kim,Yoon-Koo Kang +10 more
TL;DR: Overall survival was not significantly different between treatment groups (median overall survival 17·5 months [95% CI 16·2-19·3] in the pertuzumab group and 14·2 months [12·9-15·5) in the control group), and overall survival did not significantly improve overall survival in the intention-to-treat population.
Journal ArticleDOI
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Stephen J Luen,Roberto Salgado,Stephen B. Fox,Peter Savas,Jennifer Eng-Wong,Emma Clark,Astrid Kiermaier,Sandra M. Swain,José Baselga,Stefan Michiels,Sherene Loi +10 more
TL;DR: In patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab or placebo, higher TIL values are significantly associated with improved overall survival, suggesting that the effect of antitumour immunity extends to the advanced setting.
Journal ArticleDOI
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
Andreas Schneeweiss,Stephen Chia,Tamas Hickish,Vernon Harvey,Alexandru Eniu,M Waldron-Lynch,Jennifer Eng-Wong,Sarah Kirk,Javier Cortes +8 more
TL;DR: Long-term DFS and PFS were similar between groups and patients who achieved tpCR had improved DFS; no new safety signals were identified.
Journal ArticleDOI
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Sandra M. Swain,Michael S. Ewer,Giuseppe Viale,Suzette Delaloge,J-M Ferrero,Mark Verrill,Ramon Colomer,Cláudia Vieira,Theresa L. Werner,Hannah Douthwaite,Denise Bradley,M Waldron-Lynch,Astrid Kiermaier,Jennifer Eng-Wong,Chau T. Dang +14 more
TL;DR: Treatment with pertuzumab, trastuzumAB, and common anthracycline-containing regimens for the neoadjuvant treatment of early breast cancer resulted in cardiac and general safety profiles, and pCR rates, consistent with prior studies with pertizumab.